APA (7th ed.) Citation

Chiorean, E. G., Damle, S. R., Zhen, D. B., Whittle, M., George, B., Hochster, H., . . . Hingorani, S. (2026). Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001. Cancers, 18(3), 507. https://doi.org/10.3390/cancers18030507

Chicago Style (17th ed.) Citation

Chiorean, Elena Gabriela, et al. "Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001." Cancers 18, no. 3 (2026): 507. https://doi.org/10.3390/cancers18030507.

MLA (9th ed.) Citation

Chiorean, Elena Gabriela, et al. "Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001." Cancers, vol. 18, no. 3, 2026, p. 507, https://doi.org/10.3390/cancers18030507.